Autologous Cell Therapies Market by Source (Bone Marrow, Chondrocytes, Epidermis), Indication (Autoimmune Disorders, Cancer, Cardiovascular Disorders), End-User - Global Forecast 2024-2030

Autologous Cell Therapies Market by Source (Bone Marrow, Chondrocytes, Epidermis), Indication (Autoimmune Disorders, Cancer, Cardiovascular Disorders), End-User - Global Forecast 2024-2030


The Autologous Cell Therapies Market size was estimated at USD 8.11 billion in 2023 and expected to reach USD 9.24 billion in 2024, at a CAGR 14.52% to reach USD 20.96 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Autologous Cell Therapies Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Autologous Cell Therapies Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Autologous Cell Therapies Market, highlighting leading vendors and their innovative profiles. These include Abata Therapeutics, Achilles Therapeutics plc, Adaptimmune Therapeutics PLC, Adicet Bio Inc., AIVITA Biomedical, Inc., Aspen Neuroscienc Inc., Bellicum Phamaceuticals, Inc., BioLineRx Ltd., BioSpace, Inc., BrainStorm Cell Limited., Bristol-Myers Squibb Company, Carisma Therapeutics Inc., Catalent, Inc., Cell Therapy Catapult Ltd., Fate Therapeutics Inc., GentiBio, Inc., IASO BioTherapeutics, Kyverna Therapeutics, Inc., NOVADIP Biosciences S.A., Orchard Therapeutics Inc., T-knife Therapeutics, Inc., ThermoGenesis Holdings, Inc., Triumvira Immunologics Inc., and Vita Therapeutics, Inc..

Market Segmentation & Coverage

This research report categorizes the Autologous Cell Therapies Market to forecast the revenues and analyze trends in each of the following sub-markets:

Source

Bone Marrow
  • Chondrocytes
  • Epidermis
  • Haematopoietic Stem Cells
  • Mesenchymal Stem Cells
  • Indication

    Autoimmune Disorders
  • Cancer
  • Cardiovascular Disorders
  • Neurodegenerative Disorders
  • Orthopedics
  • Wound Healing
  • End-User

    Academics & Research Institutes
  • Ambulatory Surgical Centers
  • Hospitals & Clinics
  • Region

    Americas

    Argentina
  • Brazil
  • Canada
  • Mexico
  • United States

    California
  • Florida
  • Illinois
  • New York
  • Ohio
  • Pennsylvania
  • Texas
  • Asia-Pacific

    Australia
  • China
  • India
  • Indonesia
  • Japan
  • Malaysia
  • Philippines
  • Singapore
  • South Korea
  • Taiwan
  • Thailand
  • Vietnam
  • Europe, Middle East & Africa

    Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom
    The report offers valuable insights on the following aspects:

    1. Market Penetration: It presents comprehensive information on the market provided by key players.
    2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
    3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
    4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
    5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
    The report addresses key questions such as:

    1. What is the market size and forecast of the Autologous Cell Therapies Market?
    2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Autologous Cell Therapies Market?
    3. What are the technology trends and regulatory frameworks in the Autologous Cell Therapies Market?
    4. What is the market share of the leading vendors in the Autologous Cell Therapies Market?
    5. Which modes and strategic moves are suitable for entering the Autologous Cell Therapies Market?


    Note: PDF & Excel + Online Access - 1 Year

  • 1. Preface
    1.1. Objectives of the Study
    1.2. Market Segmentation & Coverage
    1.3. Years Considered for the Study
    1.4. Currency & Pricing
    1.5. Language
    1.6. Limitations
    1.7. Assumptions
    1.8. Stakeholders
    2. Research Methodology
    2.1. Define: Research Objective
    2.2. Determine: Research Design
    2.3. Prepare: Research Instrument
    2.4. Collect: Data Source
    2.5. Analyze: Data Interpretation
    2.6. Formulate: Data Verification
    2.7. Publish: Research Report
    2.8. Repeat: Report Update
    3. Executive Summary
    4. Market Overview
    4.1. Introduction
    4.2. Autologous Cell Therapies Market, by Region
    5. Market Insights
    5.1. Market Dynamics
    5.1.1. Drivers
    5.1.1.1. Rise in incidences of chronic diseases worldwide
    5.1.1.2. Expanding focus on drug development for new applications
    5.1.1.3. Growing need for personalized medicines with improving healthcare infrastructure
    5.1.2. Restraints
    5.1.2.1. High cost associated with autologous cell therapy
    5.1.3. Opportunities
    5.1.3.1. Technological advancements for decentralizing manufacturing of autologous cell therapy
    5.1.3.2. Rising government investments in cell-based research
    5.1.4. Challenges
    5.1.4.1. Problems associated with long turnaround time and limited shelf life
    5.2. Market Segmentation Analysis
    5.3. Market Trend Analysis
    5.4. Cumulative Impact of High Inflation
    5.5. Porter’s Five Forces Analysis
    5.5.1. Threat of New Entrants
    5.5.2. Threat of Substitutes
    5.5.3. Bargaining Power of Customers
    5.5.4. Bargaining Power of Suppliers
    5.5.5. Industry Rivalry
    5.6. Value Chain & Critical Path Analysis
    5.7. Regulatory Framework
    6. Autologous Cell Therapies Market, by Source
    6.1. Introduction
    6.2. Bone Marrow
    6.3. Chondrocytes
    6.4. Epidermis
    6.5. Haematopoietic Stem Cells
    6.6. Mesenchymal Stem Cells
    7. Autologous Cell Therapies Market, by Indication
    7.1. Introduction
    7.2. Autoimmune Disorders
    7.3. Cancer
    7.4. Cardiovascular Disorders
    7.5. Neurodegenerative Disorders
    7.6. Orthopedics
    7.7. Wound Healing
    8. Autologous Cell Therapies Market, by End-User
    8.1. Introduction
    8.2. Academics & Research Institutes
    8.3. Ambulatory Surgical Centers
    8.4. Hospitals & Clinics
    9. Americas Autologous Cell Therapies Market
    9.1. Introduction
    9.2. Argentina
    9.3. Brazil
    9.4. Canada
    9.5. Mexico
    9.6. United States
    10. Asia-Pacific Autologous Cell Therapies Market
    10.1. Introduction
    10.2. Australia
    10.3. China
    10.4. India
    10.5. Indonesia
    10.6. Japan
    10.7. Malaysia
    10.8. Philippines
    10.9. Singapore
    10.10. South Korea
    10.11. Taiwan
    10.12. Thailand
    10.13. Vietnam
    11. Europe, Middle East & Africa Autologous Cell Therapies Market
    11.1. Introduction
    11.2. Denmark
    11.3. Egypt
    11.4. Finland
    11.5. France
    11.6. Germany
    11.7. Israel
    11.8. Italy
    11.9. Netherlands
    11.10. Nigeria
    11.11. Norway
    11.12. Poland
    11.13. Qatar
    11.14. Russia
    11.15. Saudi Arabia
    11.16. South Africa
    11.17. Spain
    11.18. Sweden
    11.19. Switzerland
    11.20. Turkey
    11.21. United Arab Emirates
    11.22. United Kingdom
    12. Competitive Landscape
    12.1. FPNV Positioning Matrix
    12.2. Market Share Analysis, By Key Player
    12.3. Competitive Scenario Analysis, By Key Player
    13. Competitive Portfolio
    13.1. Key Company Profiles
    13.1.1. Abata Therapeutics
    13.1.2. Achilles Therapeutics plc
    13.1.3. Adaptimmune Therapeutics PLC
    13.1.4. Adicet Bio Inc.
    13.1.5. AIVITA Biomedical, Inc.
    13.1.6. Aspen Neuroscienc Inc.
    13.1.7. Bellicum Phamaceuticals, Inc.
    13.1.8. BioLineRx Ltd.
    13.1.9. BioSpace, Inc.
    13.1.10. BrainStorm Cell Limited.
    13.1.11. Bristol-Myers Squibb Company
    13.1.12. Carisma Therapeutics Inc.
    13.1.13. Catalent, Inc.
    13.1.14. Cell Therapy Catapult Ltd.
    13.1.15. Fate Therapeutics Inc.
    13.1.16. GentiBio, Inc.
    13.1.17. IASO BioTherapeutics
    13.1.18. Kyverna Therapeutics, Inc.
    13.1.19. NOVADIP Biosciences S.A.
    13.1.20. Orchard Therapeutics Inc.
    13.1.21. T-knife Therapeutics, Inc.
    13.1.22. ThermoGenesis Holdings, Inc.
    13.1.23. Triumvira Immunologics Inc.
    13.1.24. Vita Therapeutics, Inc.
    13.2. Key Product Portfolio
    14. Appendix
    14.1. Discussion Guide
    14.2. License & Pricing
    FIGURE 1. AUTOLOGOUS CELL THERAPIES MARKET RESEARCH PROCESS
    FIGURE 2. AUTOLOGOUS CELL THERAPIES MARKET SIZE, 2023 VS 2030
    FIGURE 3. AUTOLOGOUS CELL THERAPIES MARKET SIZE, 2018-2030 (USD MILLION)
    FIGURE 4. AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY REGION, 2023 VS 2030 (%)
    FIGURE 5. AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 6. AUTOLOGOUS CELL THERAPIES MARKET DYNAMICS
    FIGURE 7. AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2023 VS 2030 (%)
    FIGURE 8. AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 9. AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
    FIGURE 10. AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 11. AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
    FIGURE 12. AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 13. AMERICAS AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
    FIGURE 14. AMERICAS AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 15. UNITED STATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
    FIGURE 16. UNITED STATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 17. ASIA-PACIFIC AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
    FIGURE 18. ASIA-PACIFIC AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 19. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
    FIGURE 20. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 21. AUTOLOGOUS CELL THERAPIES MARKET, FPNV POSITIONING MATRIX, 2023
    FIGURE 22. AUTOLOGOUS CELL THERAPIES MARKET SHARE, BY KEY PLAYER, 2023

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook
    Cookie Settings